Innovent Biologics, Inc. is a biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases. The company is headquartered in Suzhou, Jiangsu and currently employs 6,190 full-time employees. The company went IPO on 2018-10-31. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The firm mainly conducts its businesses within domestic and overseas markets.
01801.HK stock price ended at $89.05 on Perşembe, after dropping 0.67%
On the latest trading day Feb 12, 2026, the stock price of 01801.HK fell by 0.67%, dropping from $89.50 to $89.05. During the session, the stock saw a volatility of 3.53%, with prices oscillating between a daily low of $87.75 and a high of $90.85. On the latest trading day, the trading volume for 01801.HK rose by 1.2M shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 10.1M shares were traded, with a market value of approximately $153.2B.
01801.HKTeknik Sinyalleri
Teknik Sinyaller Özeti
Satın Alma Sinyalleri 2
Nötr Sinyaller 1
Satış Sinyalleri 4
Strong Sell
Sell
Neutral
Buy
Strong Buy
01801.HK, şu anda 2 alım sinyali ve 4 satım sinyali vermektedir. Hisse senedi 12:00 AM'ten beri Aşağı yönlü trend durumundadır ve bu dönemde toplam -0.67% fiyat değişimi gerçekleşti. Genel olarak teknik göstergeler orta vadeli olarak Sell görünüm işaret etmektedir.
01801.HK için Boğa/Ayı Sinyalleri
Hareketli ortalamalar, RSI, MACD ve işlem hacmi gibi temel göstergeleri analiz ederek 01801.HK için yükseliş ve düşüş sinyalleri üretiyoruz. Bu analizlerle daha bilinçli yatırım kararları verin.